Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as GLPG2737 single dose
GLPG2737 · 2 trials · 1 indication
To assess Change from baseline in sweat chloride concentration compared to placebo.
To characterize the PK of GLPG2737 and its metabolite after a single oral dose in CF subjects.
To determine PK parameters of GLPG2737 and its metabolite after given a single oral dose in CF subjects.
To assess PK parameters of GLPG2737 and its metabolite after given a single oral dose in CF subjects.
To determine the PK of GLPG2737 and its metabolite after a single oral dose in CF subjects.
To determine the PK of GLPG2737 and its metabolite after a single oral dose in CF subjects.
To determine the PK of GLPG2737 and its metabolite after a single oral dose in CF subjects.
To determine the PK of GLPG2737 and its metabolite after a single oral dose in CF subjects.
| Arm | Type | Description |
|---|---|---|
| GLPG2737 | EXPERIMENTAL | GLPG2737 will be provided as capsules for oral use. |
| Placebo | PLACEBO_COMPARATOR | Placebo will be provided as capsules for oral use. |
| GLPG2737 single dose. | EXPERIMENTAL | Single dose of GLPG2737 oral suspension. |
| Name | Type | Description |
|---|---|---|
| GLPG2737 | DRUG | GLPG2737 oral capsules administered twice daily for 28 days on top of Orkambi. |
| Placebo | DRUG | Placebo oral capsules administered twice daily for 28 days on top of Orkambi. |
| GLPG2737 single dose | DRUG | GLPG2737 oral suspension, single dose |
Inclusion Criteria: * Male or female subject ≥18 years of age on the day of signing the ICF. * A confirmed clinical diagnosis of CF and homozygous for the F508del CFTR mutation. * Stable intake of physician prescribed Orkambi (lumacaftor 400 mg/ivacaftor 250 mg b.i.d.) for at least 12 weeks prior t...
Top 6 of 7 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | VRTX | 8 | PHASE3 | Alyftrek, Trikafta, Ivacaftor, VX-272, Tezacaftor |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| 4D Molecular Therapeutics, Inc. | FDMT | 1 | PHASE2 | 4D-710 |
| Arcturus Therapeutics Holdings, Inc. | ARCT | 1 | PHASE2 | ARCT-032 |
| Krystal Biotech, Inc. | KRYS | 1 | PHASE1 | KB407 |
| Roivant Sciences Ltd. | ROIV | 1 | PHASE1 | SP-101 |
GLPG2737 is an investigational small molecule developed by Lakefront Biotherapeutics (ticker LKFT) for cystic fibrosis, a respiratory disease. It has been studied as an oral therapy in Phase 2 and Phase 1 clinical trials, including a Phase 2 study in which it was given on top of Orkambi in adults with cystic fibrosis.
GLPG2737 is being developed for cystic fibrosis, a genetic respiratory disease. Its clinical trials enrolled adults with cystic fibrosis, including a Phase 2 study of GLPG2737 added on top of Orkambi and a Phase 1 pharmacokinetics study in male subjects with cystic fibrosis. It is investigational and has not been approved.
GLPG2737 is developed by Lakefront Biotherapeutics, which trades under the ticker LKFT. The company has sponsored the clinical studies of GLPG2737 in cystic fibrosis, including the Phase 2 trial of GLPG2737 on top of Orkambi and a Phase 1 pharmacokinetics trial.
GLPG2737 is in Phase 2 development for cystic fibrosis. Two trials have been completed: a Phase 2 study of GLPG2737 on top of Orkambi and a Phase 1 pharmacokinetics study. No trials are currently active. GLPG2737 is investigational and has not been approved by the FDA.
GLPG2737 has been studied in two completed cystic fibrosis trials. NCT03474042 was a Phase 2 trial of GLPG2737 on top of Orkambi in 22 adults, conducted in Germany. NCT03450720 was a Phase 1 pharmacokinetics trial in 6 male subjects, conducted in Belgium. Both trials are completed.
Yes, GLPG2737 single dose is another name used for GLPG2737, the investigational small molecule developed by Lakefront Biotherapeutics (ticker LKFT) for cystic fibrosis. Searches for either name refer to the same compound and the same clinical development program.